About PLUS THERAPEUTICS, Inc. Common Stock
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Market Cap
$0.01B
Employees
20
Listed Since
November 16, 2000
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Website
www.plustherapeutics.comPhone
737.255.7194
Headquarters
4200 MARATHON BLVD.
AUSTIN, TX 78756
CIK
0001095981